Lazard Asset Management LLC Reduces Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Lazard Asset Management LLC lowered its stake in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) by 65.2% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 21,442 shares of the biopharmaceutical company’s stock after selling 40,173 shares during the period. Lazard Asset Management LLC owned 0.07% of Intercept Pharmaceuticals worth $296,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of ICPT. Amalgamated Bank bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth about $66,000. Running Point Capital Advisors LLC bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth about $163,000. Clear Creek Financial Management LLC bought a new stake in shares of Intercept Pharmaceuticals in the 2nd quarter worth about $176,000. E Fund Management Co. Ltd. bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth about $186,000. Finally, Delphia USA Inc. increased its position in shares of Intercept Pharmaceuticals by 27.5% in the 1st quarter. Delphia USA Inc. now owns 16,353 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 3,523 shares during the last quarter. Institutional investors own 86.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. StockNews.com raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. HC Wainwright lowered their price objective on shares of Intercept Pharmaceuticals from $16.00 to $14.00 and set a “neutral” rating for the company in a research report on Wednesday. Cowen lowered their price objective on shares of Intercept Pharmaceuticals to $22.00 in a research report on Tuesday, August 9th. B. Riley lowered their price objective on shares of Intercept Pharmaceuticals from $30.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, August 22nd. Finally, Robert W. Baird lowered their price objective on shares of Intercept Pharmaceuticals from $52.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, October 3rd. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Intercept Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $25.80.

Intercept Pharmaceuticals Trading Down 1.1 %

Intercept Pharmaceuticals stock opened at $15.10 on Friday. The company has a quick ratio of 2.46, a current ratio of 2.46 and a debt-to-equity ratio of 2.07. The firm has a 50-day moving average price of $14.99 and a two-hundred day moving average price of $15.53. The firm has a market capitalization of $625.44 million, a price-to-earnings ratio of 2.63 and a beta of 1.14. Intercept Pharmaceuticals, Inc. has a 52-week low of $10.81 and a 52-week high of $21.25.

Intercept Pharmaceuticals Company Profile

(Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Featured Stories

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.